| scholarly article | Q13442814 |
| P50 | author | Jan Damoiseaux | Q88811764 |
| Raymond Hupperts | Q114301077 | ||
| Mariëlle Thewissen | Q130305605 | ||
| Jan Willem Cohen Tervaert | Q60901166 | ||
| Joost Smolders | Q37842476 | ||
| P2093 | author name string | Evelyn Peelen | |
| Paul Menheere | |||
| P2860 | cites work | Vitamin D and Multiple Sclerosis | Q73746172 |
| Novel insights in the immune function of the vitamin D system: synergism with interferon-beta | Q79664824 | ||
| 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis | Q81854480 | ||
| Regulatory T cell function correlates with serum 25-hydroxyvitamin D, but not with 1,25-dihydroxyvitamin D, parathyroid hormone and calcium levels in patients with relapsing remitting multiple sclerosis | Q51854507 | ||
| Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells | Q51960750 | ||
| Persistence of naive CD45RA+ regulatory T cells in adult life. | Q51986549 | ||
| Vitamin D and multiple sclerosis | Q54073705 | ||
| Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+regulatory T-cell function and FOXP3 expression | Q59149671 | ||
| Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS) | Q22241644 | ||
| Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” | Q22252938 | ||
| Interleukin-10 and the interleukin-10 receptor | Q24290912 | ||
| Foxp3 programs the development and function of CD4+CD25+ regulatory T cells | Q27860714 | ||
| Safety of vitamin D3 in adults with multiple sclerosis | Q28247094 | ||
| Multiple sclerosis | Q28299151 | ||
| CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells | Q29618394 | ||
| Functional diversity of helper T lymphocytes | Q29619415 | ||
| Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis | Q33493067 | ||
| A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible? | Q33727856 | ||
| UV radiation suppresses experimental autoimmune encephalomyelitis independent of vitamin D production. | Q33778814 | ||
| A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis | Q33899901 | ||
| Cytokine profile in patients with multiple sclerosis following vitamin D supplementation | Q34167807 | ||
| Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis | Q34311395 | ||
| Vitamin D as an immune modulator in multiple sclerosis, a review | Q37051712 | ||
| Epidemiology of multiple sclerosis: from risk factors to prevention | Q37078979 | ||
| Short- and long-term safety of weekly high-dose vitamin D3 supplementation in school children. | Q37311303 | ||
| 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis | Q37445672 | ||
| Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism | Q37622058 | ||
| Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis | Q39110932 | ||
| Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia | Q39136547 | ||
| Immunomodulatory effects of Vitamin D in multiple sclerosis | Q39868289 | ||
| Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis | Q42418046 | ||
| Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. | Q43197058 | ||
| Glatiramer acetate improves regulatory T-cell function by expansion of naive CD4(+)CD25(+)FOXP3(+)CD31(+) T-cells in patients with multiple sclerosis. | Q45914495 | ||
| Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis | Q46463661 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vitamin | Q34956 |
| multiple sclerosis | Q8277 | ||
| cholecalciferol | Q139347 | ||
| vitamin D | Q175621 | ||
| P304 | page(s) | e15235 | |
| P577 | publication date | 2010-12-13 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis | |
| P478 | volume | 5 |
| Q37993298 | A 21st century evaluation of the safety of oral vitamin D |
| Q90074397 | Brief Report: Markers of Spontaneous Preterm Delivery in Women Living With HIV: Relationship With Protease Inhibitors and Vitamin D |
| Q36353718 | Calcitriol modulates the CD46 pathway in T cells |
| Q36158139 | Cholecalciferol Plus Calcium Suppresses Abnormal PBMC Reactivity in Patients with Multiple Sclerosis |
| Q47742937 | Circulating vitamin D binding protein levels are not associated with relapses or with vitamin D status in multiple sclerosis |
| Q84831930 | Comment on the article by Allen et al. ‘A pilot study of the immunological effects of high-dose vitamin D in healthy volunteers’ |
| Q36638670 | Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis |
| Q38588203 | Controversy and consensus regarding vitamin D: Recent methodological changes and the risks and benefits of vitamin D supplementation |
| Q46343725 | Daily Cholecalciferol Supplementation during Pregnancy Alters Markers of Regulatory Immunity, Inflammation, and Clinical Outcomes in a Randomized Controlled Trial |
| Q91646619 | Divergent Effect of Tacalcitol (PRI-2191) on Th17 Cells in 4T1 Tumor Bearing Young and Old Ovariectomized Mice |
| Q36396585 | Effect of high-dose vitamin D3 intake on ambulation, muscular pain and bone mineral density in a woman with multiple sclerosis: a 10-year longitudinal case report |
| Q39737347 | Effect of vitamin D(3) supplementation on peripheral B cell differentiation and isotype switching in patients with multiple sclerosis |
| Q64093613 | Effectiveness of Vitamin D Supplementation in the Management of Multiple Sclerosis: A Systematic Review |
| Q42364107 | Effects of vitamin D3 in clinically isolated syndrome and healthy control participants: A double-blind randomised controlled trial |
| Q39069015 | Effects of vitamin D3, calcipotriol and FTY720 on the expression of surface molecules and cytolytic activities of human natural killer cells and dendritic cells. |
| Q37428539 | Emerging Concepts on the Gut Microbiome and Multiple Sclerosis. |
| Q39509517 | Fat-soluble vitamins as disease modulators in multiple sclerosis |
| Q64119115 | Focus on 1,25-Dihydroxyvitamin D3 in the Peripheral Nervous System |
| Q38387302 | Genetic polymorphisms related to vitamin D and the therapeutic potential of vitamin D in multiple sclerosis |
| Q90248409 | High-Dose Vitamin D-Mediated Hypercalcemia as a Potential Risk Factor in Central Nervous System Demyelinating Disease |
| Q39356640 | High-dose cholecalciferol supplementation significantly increases peripheral CD4⁺ Tregs in healthy adults without negatively affecting the frequency of other immune cells |
| Q34681985 | Influence of Diet in Multiple Sclerosis: A Systematic Review. |
| Q36050928 | Low-dose oral cholecalciferol is associated with higher numbers of Helios(+) and total Tregs than oral calcitriol in renal allograft recipients: an observational study |
| Q36084601 | Mapping Variation in Cellular and Transcriptional Response to 1,25-Dihydroxyvitamin D3 in Peripheral Blood Mononuclear Cells |
| Q48354362 | Molecular Genetic and Epigenetic Basis of Multiple Sclerosis |
| Q41886918 | Paradigms in multiple sclerosis: time for a change, time for a unifying concept |
| Q47140852 | Physiological serum 25-hydroxyvitamin D concentrations are associated with improved thyroid function-observations from a community-based program. |
| Q35956133 | Prevention and treatment of MS: studying the effects of vitamin D |
| Q41872258 | Promoting return of function in multiple sclerosis: An integrated approach |
| Q90597388 | Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon β-1a |
| Q42223350 | Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation |
| Q44539393 | Relatively high serum vitamin D levels do not impair the antibody response to encapsulated bacteria |
| Q44582650 | Response to comment on the article by Allen et al. 'A pilot study of the immunological effects of high-dose vitamin D in healthy volunteers'. |
| Q38210581 | Role of vitamin D in acquired immune and autoimmune diseases |
| Q58389952 | Role of vitamin D in multiple sclerosis: implications for disease management |
| Q36645164 | Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. |
| Q28481469 | Statin-associated polymyalgia rheumatica. An analysis using WHO global individual case safety database: a case/non-case approach |
| Q91596387 | The impact of vitamin D3 intake on inflammatory markers in multiple sclerosis patients and their first-degree relatives |
| Q35741861 | The initiation and prevention of multiple sclerosis |
| Q30388273 | The multiple sclerosis susceptibility genes TAGAP and IL2RA are regulated by vitamin D in CD4+ T cells. |
| Q38184977 | The potential role of epigenetic modifications in the heritability of multiple sclerosis |
| Q90255463 | The role of vitamin D in increasing circulating T regulatory cell numbers and modulating T regulatory cell phenotypes in patients with inflammatory disease or in healthy volunteers: A systematic review |
| Q26780466 | Update in vitamin D and multiple sclerosis |
| Q38125058 | Update on Therapeutic Options for Multiple Sclerosis |
| Q28081150 | Vitamin D Actions on CD4(+) T Cells in Autoimmune Disease |
| Q36045080 | Vitamin D Status Does Not Affect Disability Progression of Patients with Multiple Sclerosis over Three Year Follow-Up |
| Q60916990 | Vitamin D Supplementation in Central Nervous System Demyelinating Disease-Enough Is Enough |
| Q47306228 | Vitamin D and Multiple Sclerosis: A Comprehensive Review |
| Q47171978 | Vitamin D and Neurological Diseases: An Endocrine View |
| Q33806322 | Vitamin D and inflammatory diseases |
| Q38024285 | Vitamin D and multiple sclerosis: a critical review and recommendations on treatment |
| Q36751056 | Vitamin D and multiple sclerosis: epidemiology, immunology, and genetics |
| Q33592080 | Vitamin D deficiency as a risk factor for the development of autoantibodies in patients with ASIA and silicone breast implants: a cohort study and review of the literature |
| Q35086209 | Vitamin D deficiency induces Th2 skewing and eosinophilia in neonatal allergic airways disease |
| Q34550631 | Vitamin D in Autoimmunity: Molecular Mechanisms and Therapeutic Potential. |
| Q38067276 | Vitamin D in Systemic and Organ-Specific Autoimmune Diseases |
| Q43514969 | Vitamin D supplementation and antibodies against the Epstein-Barr virus in multiple sclerosis patients |
| Q40969344 | Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis |
| Q85337953 | Vitamin D3 metabolite calcidiol primes human dendritic cells to promote the development of immunomodulatory IL-10-producing T cells |
| Q36329622 | Vitamin D₃ and monomethyl fumarate enhance natural killer cell lysis of dendritic cells and ameliorate the clinical score in mice suffering from experimental autoimmune encephalomyelitis. |
| Q48162662 | Wellness and the Role of Comorbidities in Multiple Sclerosis. |
| Q34165582 | Widespread vitamin D insufficiency: A new challenge for primary prevention, with particular reference to multiple sclerosis |
Search more.